{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-002893","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2023-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.894285+00:00","generated_at":"2026-06-19T11:02:10.151463+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Assembly Biosciences nominates first herpesvirus candidate ABI-5366, a long-acting HSV-2 helicase inhibitor","bullets":["ABI-5366 is a long-acting HSV-2 helicase inhibitor targeting high-recurrence genital herpes; IND-enabling studies initiated.","Preclinical data show nanomolar potency in vitro and exceptionally low clearance, supporting at least monthly dosing.","Company plans to file IND/CTA in first half of 2024; more data expected at scientific conferences in 2023.","First development candidate from Assembly Bio's expanded focus beyond hepatitis B.","Current therapies for high-recurrence genital herpes are only partially effective; helicase inhibitors previously showed greater reductions in shedding and lesions."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-002893","json":"https://secwatch.observer/filing/0000950170-23-002893.json","markdown":"https://secwatch.observer/filing/0000950170-23-002893.md","text":"https://secwatch.observer/filing/0000950170-23-002893.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017023002893/0000950170-23-002893-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017023002893/asmb-20230215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T11:02:10.151463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}